Quick Takeaways
- ORBIMED ADVISORS LLC filed SCHEDULE 13G/A for CytomX Therapeutics, Inc. Common Stock, par value $0.00001 per share (CTMX).
- Disclosed ownership: 2.1%.
- Date of event: 31 Dec 2025.
ORBIMED ADVISORS LLC - 31 Dec 2025 SCHEDULE 13G/A Report for CytomX Therapeutics, Inc. Common Stock, par value $0.00001 per share (CTMX)
- Filing Manager
- ORBIMED ADVISORS LLC
- Reporting Manager
- OrbiMed Advisors LLC
- Symbol
- CTMX
- Shares outstanding
- 167,888,095 shares
- Disclosed Ownership
- 3,525,650 shares
- Ownership
- 2.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 18:23:44 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ORBIMED ADVISORS LLC disclosed 2.1% ownership in CytomX Therapeutics, Inc. Common Stock, par value $0.00001 per share (CTMX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Aug 2025.
- Current filing was accepted on 17 Feb 2026, 18:23.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 2.1% | 3,525,650 | 0 | 3,525,650 | /s/ Carl L. Gordon | Carl L. Gordon / Member of OrbiMed Advisors LLC |